MX2018015464A - Uso de benzoato de litio para tratar trastornos del sistema nervioso central. - Google Patents

Uso de benzoato de litio para tratar trastornos del sistema nervioso central.

Info

Publication number
MX2018015464A
MX2018015464A MX2018015464A MX2018015464A MX2018015464A MX 2018015464 A MX2018015464 A MX 2018015464A MX 2018015464 A MX2018015464 A MX 2018015464A MX 2018015464 A MX2018015464 A MX 2018015464A MX 2018015464 A MX2018015464 A MX 2018015464A
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
lithium benzoate
treating central
system disorders
Prior art date
Application number
MX2018015464A
Other languages
English (en)
Inventor
Emil Tsai Guochuan
Jung CHEN Hong-
En Hsu Wei-
CHANG Weiju
Jia Huang Jing-
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Publication of MX2018015464A publication Critical patent/MX2018015464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

Metodos para tratar los trastornos del sistema nervioso central (SNC) o atenuar el dolor con un compuesto de benzoato de litio.
MX2018015464A 2016-06-13 2017-06-13 Uso de benzoato de litio para tratar trastornos del sistema nervioso central. MX2018015464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349600P 2016-06-13 2016-06-13
PCT/CN2017/088043 WO2017215591A1 (en) 2016-06-13 2017-06-13 Use of lithium benzoate for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
MX2018015464A true MX2018015464A (es) 2019-05-27

Family

ID=60663976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015464A MX2018015464A (es) 2016-06-13 2017-06-13 Uso de benzoato de litio para tratar trastornos del sistema nervioso central.

Country Status (9)

Country Link
US (1) US10668032B2 (es)
EP (1) EP3468550A4 (es)
JP (2) JP2019521117A (es)
KR (1) KR102512891B1 (es)
CN (1) CN109562089A (es)
CA (1) CA3027290A1 (es)
IL (1) IL263494B2 (es)
MX (1) MX2018015464A (es)
WO (1) WO2017215591A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4034136A4 (en) * 2019-06-19 2023-07-05 The United States Government As Represented By The Department Of Veterans Affairs FORMULATIONS CONTAINING LITHIUM FOR THE TREATMENT OF GOUTY ARTHROPATHY
US11850259B2 (en) 2020-10-05 2023-12-26 The United States Government As Represented By The Department Of Veterans Affairs Methods of treating viral infections affecting the respiratory tract using topically administered lithium agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
SE504098C2 (sv) * 1993-11-24 1996-11-11 Tl Vent Ab Avskiljare för ett elektrofilter
DE59409129D1 (de) 1993-11-26 2000-03-09 Karla Lehmann Verwendung von lithiumverbindungen zur behandlung und prophylaxe des morbus alzheimer
JPH11279066A (ja) * 1998-03-25 1999-10-12 Mitsubishi Chemical Corp リチウム塩を有効成分とする神経細胞死抑制剤
DK1551793T3 (en) * 2002-06-19 2016-04-25 Gnt Pharma Co Ltd Tetrafluorobenzyl derivatives and pharmaceutical compositions containing these for the prevention and treatment of acute and chronic neurodegenerative diseases of the central nervous system
SI1619180T1 (sl) 2003-04-23 2010-04-30 Japan Tobacco Inc Antagonist CaSR
JP5006311B2 (ja) * 2005-05-25 2012-08-22 チョンワエ ファーマ コーポレーション 置換テトラフルオロベンジルアニリン化合物、及びその薬学的に許容される塩の製造方法
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
BRPI0718114A2 (pt) * 2006-11-01 2017-01-10 Univ Rutgers método para estimular a produção de fator de crescimento por células de sangue de cordão umbilical humano, método in vitro para expandir células de sangue de cordão umbilical humano, e, método para melhorar sobrevivência e crescimento de células de sangue de cordão umbilical humano transplantadas em um indivíduo
CN100515428C (zh) * 2007-04-26 2009-07-22 暨南大学 钨酸锂在制药中的应用
US20130338199A1 (en) 2008-07-11 2013-12-19 Uday Saxena Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
CN102292094B (zh) * 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
EP3636629A1 (en) 2010-07-23 2020-04-15 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
PL2649044T3 (pl) * 2010-12-08 2018-02-28 Grünenthal GmbH Sposób syntezy podstawionych pochodnych aminocykloheksanonu
US20130017274A1 (en) * 2011-03-16 2013-01-17 Buck Institute For Research On Aging Low dose lithium in the treatment or prophylaxis of parkinson's disease
JP2014508814A (ja) 2011-03-24 2014-04-10 ユニバーシティ・オブ・サウス・フロリダ リチウム組成物
US9120766B2 (en) 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
RU2582962C1 (ru) * 2014-12-23 2016-04-27 Ольга Алексеевна Громова Средство для профилактики и лечения нейродегенеративной патологии и сосудистой деменции (варианты)

Also Published As

Publication number Publication date
RU2019100426A3 (es) 2020-07-14
CN109562089A (zh) 2019-04-02
EP3468550A4 (en) 2020-02-12
KR102512891B1 (ko) 2023-03-21
JP2022017334A (ja) 2022-01-25
IL263494A (en) 2019-01-31
RU2019100426A (ru) 2020-07-14
IL263494B1 (en) 2023-09-01
EP3468550A1 (en) 2019-04-17
CA3027290A1 (en) 2017-12-21
KR20190017940A (ko) 2019-02-20
US20180318243A1 (en) 2018-11-08
US10668032B2 (en) 2020-06-02
WO2017215591A1 (en) 2017-12-21
JP2019521117A (ja) 2019-07-25
IL263494B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2018001447A (es) Bloqueadores de canal de ion cargado y metodos para su uso.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
NZ738672A (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
EP3402477A4 (en) METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
IL267818A (en) Methods for treating neurological disorders
IL281736A (en) Methods for treating myeloproliferative diseases
IL275654A (en) Methods of treating CASTOR-related disorders
MX2021006439A (es) Reguladores del cftr y metodos para su uso.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2018015464A (es) Uso de benzoato de litio para tratar trastornos del sistema nervioso central.
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
IL281589A (en) Methods for treating myeloproliferative diseases
ZA201700037B (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
EP3638223C0 (en) BROMHEXINE FOR THE TREATMENT OF PAIN
SG11202105279SA (en) Methods of treating myeloproliferative disorders
GB201700502D0 (en) Treatment of tumours of the central nervous system